US 12,419,876 B2
Treatment of hearing loss by inhibition of casein kinase 1
Albert Edge, Brookline, MA (US); and Yenfu Cheng, Boston, MA (US)
Assigned to Massachusetts Eye and Ear Infirmary, Boston, MA (US)
Filed by Massachusetts Eye and Ear Infirmary, Boston, MA (US)
Filed on Oct. 8, 2021, as Appl. No. 17/450,377.
Application 17/450,377 is a division of application No. 15/781,041, granted, now 11,185,536, previously published as PCT/US2016/064727, filed on Dec. 2, 2016.
Claims priority of provisional application 62/263,412, filed on Dec. 4, 2015.
Prior Publication US 2022/0016100 A1, Jan. 20, 2022
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 31/437 (2006.01); A61K 9/00 (2006.01); A61K 31/4439 (2006.01); A61K 38/00 (2006.01); A61P 27/16 (2006.01); C07D 401/04 (2006.01); C07D 403/04 (2006.01); C07D 405/14 (2006.01); C07D 413/14 (2006.01); C07D 487/04 (2006.01); C12Q 1/48 (2006.01)
CPC A61K 31/4439 (2013.01) [A61K 9/0046 (2013.01); A61K 31/437 (2013.01); A61K 38/00 (2013.01); A61P 27/16 (2018.01); C07D 401/04 (2013.01); C07D 403/04 (2013.01); C07D 405/14 (2013.01); C07D 413/14 (2013.01); C07D 487/04 (2013.01); C12Q 1/485 (2013.01); G01N 2800/14 (2013.01)] 14 Claims
 
1. A method of treating a subject who has or is at risk of developing hearing loss or vestibular dysfunction, the method comprising:
identifying a subject who has experienced, or is at risk for developing, hearing loss or vestibular dysfunction; and
administering to the subject one or more nucleic acids that target casein kinase 1 (CK1) epsilon and/or CK1 delta, and one or more compounds that stimulate Atoh1 gene expression.